Skip to main content

Advertisement

SpringerLink
Log in

Papillary thyroid cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Papillary thyroid cancer (PTC), the most common thyroid malignancy, is associated with an excellent prognosis. Overall survival is more than 90%. The first-line treatment is surgical excision, and although the debate continues as to whether a total thyroidectomy or thyroid lobectomy should be recommended, most patients at the University of California, San Francisco are treated with a total thyroidectomy. Not only has this been shown to be superior for overall survival in select patient populations, but local recurrence is also significantly lower with this approach. Total thyroidectomy also optimizes the adjuvant treatment options that are unique to “differentiated” thyroid cancer because these malignant cells retain many of the features of the native thyroid follicular cell. These cellular features are used for specialized investigations and treatment options in patients with PTC. For example, PTC cells retain the ability to produce thyroglobulin, to be stimulated by thyroidstimulating hormone (TSH), and to take up iodine. These features are vital and separate differentiated thyroid cancer from other epithelial malignancies because such features can be used in clinical follow-up (monitoring serum thyroglobulin levels, whole body radioactive iodine scans) and in the treatment of patients with PTC (TSH suppression, radioactive iodine ablation of thyroid remnant, local recurrences, and regional or distant metastases). In summary, the wide array of treatment options for patients with PTC includes surgery, radioactive iodine, thyroid hormone suppression of TSH, external beam radiation (less commonly), and rarely, chemotherapy. This continues to be an area of exciting research for emerging therapy, much of which concentrates on enhancing or re-establishing the differentiated features of the thyroid cancer cell, in an effort to optimize the adjuvant treatment options. The treatment options that are chosen depend on patient factors, disease factors, and the decisions of the patient and treatment team.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Silver RJ, Parangi A: Management of thyroid incidentalomas. Surg Clin North Am 2004, 84:907–919.

    Article  PubMed  Google Scholar 

  2. Baskin HJ: Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules and multinodular goiters. Endocr Pract 2004, 10:242–245.

    PubMed  Google Scholar 

  3. Agrawal S: Diagnostic accuracy and role of fine needle aspiration cytology in management of thyroid nodules. J Surg Oncol 1995, 58:168–172.

    Article  PubMed  CAS  Google Scholar 

  4. Woeber KA: Cost-effective evaluation of the patient with a thyroid nodule. Surg Clin North Am 1995, 75:357–363.

    PubMed  CAS  Google Scholar 

  5. Punthakee X, Palme CE, Franklin JH, et al.: Fine-needle aspiration biopsy findings suspicious for papillary thyroid carcinoma: a review of cytopathological criteria. Laryngoscope 2005, 115:433–436.

    Article  PubMed  Google Scholar 

  6. Brierley JD, Tsang RW: External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clin North Am 1996, 25:141–157.

    Article  PubMed  CAS  Google Scholar 

  7. Ringel MD, Ladenson PW: Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 2004, 11:97–116.

    Article  PubMed  CAS  Google Scholar 

  8. Repchinsky C: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals, vol. 537. Ottawa, Canada: CP Association; 2004:1948–1951.

    Google Scholar 

  9. Caron NR, Clark OH: Well differentiated thyroid cancer. Scand J Surg 2004, 93:261–271.

    PubMed  CAS  Google Scholar 

  10. Kebebew E, Clark OH: Differentiated thyroid cancer: “complete≓ rational approach. World J Surg 2000, 24:942–951.

    Article  PubMed  CAS  Google Scholar 

  11. Caron NR, Clark OH: Papillary thyroid cancer: surgical management of lymph node metastases. Curr Treat Options Oncol 2005, 6:311–322. With the increased incidence of lymph node metastases in patients with PTC, this review on the treatment of metastatic PTC is an excellent complement to this current review on primary PTC.

    PubMed  Google Scholar 

  12. Angelos P: Current approaches to the treatment of welldifferentiated thyroid cancer. Oncology (Williston Park) 2002, 16:309–315; discussion 315, 318, 323-324.

    Google Scholar 

  13. Dackiw AP, Zeiger M: Extent of surgery for differentiated thyroid cancer. Surg Clin North Am 2004, 84:817–832. Because surgery is the main treatment for primary PTC, this paper is an excellent review of the long-standing debate on the extent of surgery required for optimal treatment of patients with PTC.

    Article  PubMed  Google Scholar 

  14. Caron NR, Tan YY, Ogilvie JB et al.: Selective modified radical neck dissection for papillary thyroid cancer--is level I, II and V dissection always necessary. World J Surg 2006, 30:1–8.

    Article  Google Scholar 

  15. Caron NR, Sturgeon C, Clark OH: The specialist endocrine surgeon. In Practical Management of Thyroid Cancer--A Multidisciplinary Approach. Edited by Mazzaferri EL. London: Springer; 2005:121–134.

    Google Scholar 

  16. Weigel RJ: Advances in the diagnosis and management of well-differentiated thyroid cancers. Curr Opin Oncol 1996, 8:37–43.

    PubMed  CAS  Google Scholar 

  17. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418–428.

    Article  PubMed  CAS  Google Scholar 

  18. Wartofsky L, Sherman SI, Gopal J, et al.: The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998, 83:4195–4203. This is a good review of some of the challenging questions about RAI that emerge when following and/or treating a patient with PTC.

    Article  PubMed  CAS  Google Scholar 

  19. Cailleux AF, Baudin E, Travagli JP, et al.: Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer. J Clin Endocrinol Metab 2000, 85:175–178.

    Article  PubMed  CAS  Google Scholar 

  20. Loh KC, Greenspan FS, Gee L, et al.: Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997, 82:3553–3562.

    Article  PubMed  CAS  Google Scholar 

  21. Ford D, Giridharan S, McConkey C, et al.: External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2003, 15:337–341. The authors provide a review of previous studies on external beam radiation treatment for patients with differentiated thyroid cancer and subsequently review their own data that confirmed the challenging nature of treatment for this small but significant patient population.

    CAS  Google Scholar 

  22. Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990, 19:545–576.

    PubMed  CAS  Google Scholar 

  23. Kebebew E, Clark OH: Papillary thyroid cancer. In Surgical Endocrinology. Edited by Doherty GM, Skogseid B. Philadelphia: Lippincott Williams & Wilkins; 2001:59–73.

    Google Scholar 

  24. Park JW, Clark OH: Redifferentiation therapy for thyroid cancer. Surg Clin North Am 2004, 84:921–943. An excellent, concise overview of emerging redifferentiating therapy options for patients with well-differentiated thyroid cancer who fail conventional treatment methods.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Zion Medical Center, University of California, San Francisco, Room C-347, 1600 Divisadero Street, 94143, San Francisco, CA, USA

    Orlo H. Clark MD

Authors
  1. Nadine R. Caron MD, MPH, FRCFC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orlo H. Clark MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caron, N.R., Clark, O.H. Papillary thyroid cancer. Curr. Treat. Options in Oncol. 7, 309–319 (2006). https://doi.org/10.1007/s11864-006-0040-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0040-7

Keywords

Search

Navigation